| abstract |
The instant invention is based, at least in part on the finding that binding molecules which bind to different epitopes within IGF-IR result in improved IGF-I and/or IGF-2 blocking capabilities when compared to binding molecules that bind to a single IGF-IR epitope. The instant invention provides compositions that bind to multiple epitopes of IGF-IR, for example, combinations of monospecific binding molecules or multispecific binding molecules (e.g., bispecific molecules). Methods of making the subject binding molecules and methods of using the binding molecules of the invention to antagonize IGF-IR signaling are also provided. |